Epidermolysis Bullosa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Epidermolysis Bullosa Pipeline Drugs Market Overview

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Epidermolysis Bullosa – Drugs In Development, 2022, provides an overview of the Epidermolysis Bullosa (Dermatology) pipeline landscape.

Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Symptoms include blistering of skin, deformity or loss of fingernails and toenails, internal blistering, including on the throat, esophagus, upper airway, stomach, intestines and urinary tract, skin thickening on palms and soles of the feet (hyperkeratosis) and scalp blistering, scarring and hair loss (scarring alopecia). Treatment includes antibiotics, antibiotic and surgery.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Epidermolysis Bullosa – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epidermolysis Bullosa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Epidermolysis Bullosa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 4, 11, 2, 2, 13, 9 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 1 molecules, respectively.

Epidermolysis Bullosa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Epidermolysis Bullosa (Dermatology).

– The pipeline guide reviews pipeline therapeutics for Epidermolysis Bullosa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Epidermolysis Bullosa (Dermatology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Epidermolysis Bullosa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Epidermolysis Bullosa (Dermatology)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Epidermolysis Bullosa (Dermatology).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Epidermolysis Bullosa (Dermatology) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Abeona Therapeutics Inc
Aegle Therapeutics Corp
Almirall SA
Amniotics AB
Amryt Pharma Plc
Anterogen Co Ltd
Avicanna Inc
Berg LLC
Biomendics LLC
Branca Bunus Ltd
Carocell Bio Ltd
Castle Creek Biosciences Inc
Celularity Inc
Constant Therapeutics LLC
CSA Biotechnologies LLC
Daewoong Pharmaceutical Co Ltd
Eloxx Pharmaceuticals Inc
Energenesis Biomedical Co Ltd
FIBRX Derm Inc
Holostem Terapie Avanzate SRL
Immusoft Corp
InMed Pharmaceuticals Inc
Kangstem Biotech Co Ltd
Krystal Biotech Inc
LambdaGen Therapeutics
Mariposa Therapeutics Ltd
Onconova Therapeutics Inc
OTR3 SAS
Palvella Therapeutics LLC
Panag Pharma Inc
Phoenix Tissue Repair Inc
Quoin Pharmaceuticals Ltd
RegeneRx Biopharmaceuticals Inc
Relief Therapeutics Holding AG
RHEACELL GmbH & Co KG
Shionogi & Co Ltd
StemRIM Inc
Therapicon Srl
TWi Biotechnology Inc
Vera Therapeutics Inc
Wings Therapeutics

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Epidermolysis Bullosa – Overview

Epidermolysis Bullosa – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Epidermolysis Bullosa – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Epidermolysis Bullosa – Companies Involved in Therapeutics Development

Epidermolysis Bullosa – Drug Profiles

Epidermolysis Bullosa – Dormant Projects

Epidermolysis Bullosa – Discontinued Products

Epidermolysis Bullosa – Product Development Milestones

Featured News & Press Releases

Jul 26, 2022: InMed enrols first adolescent in Phase II epidermolysis bullosa trial

Jun 22, 2022: Krystal Biotech submits biologics license application to U.S. FDA seeking approval of B-VEC for the treatment of patients with dystrophic epidermolysis bullosa

May 23, 2022: Phoenix Tissue Repair report positive Phase II epidermolysis bullosa drug trial data

May 19, 2022: Krystal Biotech to present additional data on B-VEC from the GEM-3 Phase 3 study at the Society for Investigative Dermatology Annual Meeting

May 18, 2022: Tetra Bio-Pharma receives EMA Orphan Drug Designation for a novel topical therapeutic containing CBD

Apr 11, 2022: Krystal Biotech announces home dosing in B-VEC open label extension study

Mar 28, 2022: Krystal Biotech announces publication of phase 1 and 2 clinical trial (GEM 1/2 Study) of beremagene geperpavec (B-VEC) data in Nature Medicine

Mar 26, 2022: New GEM-3 phase 3 results for B-VEC presented at 2022 American Academy of Dermatology Annual Meeting

Mar 18, 2022: Krystal Biotech to present at 2022 American Academy of Dermatology annual meeting

Mar 14, 2022: Abeona Therapeutics achieves target enrollment in pivotal phase 3 VIITAL study of EB-101 in RDEB

Nov 30, 2021: Krystal’s dystrophic EB gene therapy trial meets primary goal

Nov 18, 2021: Abeona Therapeutics announces support of EB research partnership’s venture into cures event to raise awareness for education and research of epidermolysis bullosa

Oct 26, 2021: Krystal Biotech announces completion of the GEM-3 pivotal phase 3 study evaluating B-VEC for the treatment of dystrophic epidermolysis bullosa

Oct 21, 2021: Castle Creek Biosciences awarded FDA Orphan products development grant to support DeFi-RDEB, a pivotal phase 3 study of FCX-007 investigational gene therapy for recessive dystrophic epidermolysis bullosa

Sep 30, 2021: InMed Pharmaceuticals announces commencement of phase 2 clinical trial investigating cannabinol (CBN), a rare cannabinoid, in the treatment of epidermolysis bullosa

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Epidermolysis Bullosa, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Epidermolysis Bullosa – Pipeline by Abeona Therapeutics Inc, 2022

Epidermolysis Bullosa – Pipeline by Aegle Therapeutics Corp, 2022

Epidermolysis Bullosa – Pipeline by Almirall SA, 2022

Epidermolysis Bullosa – Pipeline by Amniotics AB, 2022

Epidermolysis Bullosa – Pipeline by Amryt Pharma Plc, 2022

Epidermolysis Bullosa – Pipeline by Anterogen Co Ltd, 2022

Epidermolysis Bullosa – Pipeline by Avicanna Inc, 2022

Epidermolysis Bullosa – Pipeline by Berg LLC, 2022

Epidermolysis Bullosa – Pipeline by Biomendics LLC, 2022

Epidermolysis Bullosa – Pipeline by Branca Bunus Ltd, 2022

Epidermolysis Bullosa – Pipeline by Carocell Bio Ltd, 2022

Epidermolysis Bullosa – Pipeline by Castle Creek Biosciences Inc, 2022

Epidermolysis Bullosa – Pipeline by Celularity Inc, 2022

Epidermolysis Bullosa – Pipeline by Constant Therapeutics LLC, 2022

Epidermolysis Bullosa – Pipeline by CSA Biotechnologies LLC, 2022

Epidermolysis Bullosa – Pipeline by Daewoong Pharmaceutical Co Ltd, 2022

Epidermolysis Bullosa – Pipeline by Eloxx Pharmaceuticals Inc, 2022

Epidermolysis Bullosa – Pipeline by Energenesis Biomedical Co Ltd, 2022

Epidermolysis Bullosa – Pipeline by FIBRX Derm Inc, 2022

Epidermolysis Bullosa – Pipeline by Holostem Terapie Avanzate SRL, 2022

Epidermolysis Bullosa – Pipeline by Immusoft Corp, 2022

Epidermolysis Bullosa – Pipeline by InMed Pharmaceuticals Inc, 2022

Epidermolysis Bullosa – Pipeline by Kangstem Biotech Co Ltd, 2022

Epidermolysis Bullosa – Pipeline by Krystal Biotech Inc, 2022

Epidermolysis Bullosa – Pipeline by LambdaGen Therapeutics, 2022

Epidermolysis Bullosa – Pipeline by Mariposa Therapeutics Ltd, 2022

Epidermolysis Bullosa – Pipeline by Onconova Therapeutics Inc, 2022

Epidermolysis Bullosa – Pipeline by OTR3 SAS, 2022

Epidermolysis Bullosa – Pipeline by Palvella Therapeutics LLC, 2022

Epidermolysis Bullosa – Pipeline by Panag Pharma Inc, 2022

Epidermolysis Bullosa – Pipeline by Phoenix Tissue Repair Inc, 2022

Epidermolysis Bullosa – Pipeline by Quoin Pharmaceuticals Ltd, 2022

Epidermolysis Bullosa – Pipeline by RegeneRx Biopharmaceuticals Inc, 2022

Epidermolysis Bullosa – Pipeline by Relief Therapeutics Holding AG, 2022

Epidermolysis Bullosa – Pipeline by RHEACELL GmbH & Co KG, 2022

Epidermolysis Bullosa – Pipeline by Shionogi & Co Ltd, 2022

Epidermolysis Bullosa – Pipeline by StemRIM Inc, 2022

Epidermolysis Bullosa – Pipeline by Therapicon Srl, 2022

Epidermolysis Bullosa – Pipeline by TWi Biotechnology Inc, 2022

Epidermolysis Bullosa – Pipeline by Vera Therapeutics Inc, 2022

Epidermolysis Bullosa – Pipeline by Wings Therapeutics, 2022

Epidermolysis Bullosa – Dormant Projects, 2022

Epidermolysis Bullosa – Dormant Projects, 2022 (Contd..1)

Epidermolysis Bullosa – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Epidermolysis Bullosa, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Epidermolysis Bullosa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Epidermolysis Bullosa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Epidermolysis Bullosa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.